filmov
tv
RETIRAN VACUNA COVID-19 ASTRAZENECA

Показать описание
En este vídeo respondo a algunas preguntas sobre la retirada de la vacuna contra el covid-19 de AstraZeneca (Vaxzevria). También doy respuesta a algunas inquietudes relacionadas con las vacunas ARN-m (Pfizer/BioNTech Y Moderna) y su tecnología de ingeniería genética.
CONTENIDOS
0:00 Motivación del vídeo
0:27 Tribunales y retirada de la vacuna
7:02 Respuesta a críticas a las vacunas ARN-m
Dr. Alberto Sanagustín
#alsanagust
REFERENCIAS
Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931. Published 2021 Aug 26. doi:10.1136/bmj.n1931
Florentino PTV, Millington T, Cerqueira-Silva T, et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. Lancet Infect Dis. 2022;22(11):1577-1586. doi:10.1016/S1473-3099(22)00451-0
Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data [published correction appears in Lancet. 2021 Jul 17;398(10296):212]. Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ. 2022;376:e069052. Published 2022 Feb 10. doi:10.1136/bmj-2021-069052
CONTENIDOS
0:00 Motivación del vídeo
0:27 Tribunales y retirada de la vacuna
7:02 Respuesta a críticas a las vacunas ARN-m
Dr. Alberto Sanagustín
#alsanagust
REFERENCIAS
Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931. Published 2021 Aug 26. doi:10.1136/bmj.n1931
Florentino PTV, Millington T, Cerqueira-Silva T, et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. Lancet Infect Dis. 2022;22(11):1577-1586. doi:10.1016/S1473-3099(22)00451-0
Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data [published correction appears in Lancet. 2021 Jul 17;398(10296):212]. Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ. 2022;376:e069052. Published 2022 Feb 10. doi:10.1136/bmj-2021-069052
Комментарии